查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1418372

被忽视的热带疾病诊断市场报告：2030 年趋势、预测与竞争分析

Neglected Tropical Disease Diagnosis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

被忽视的热带疾病诊断（NTD）的趋势和预测

预计 2024 年至 2030 年，全球被忽视的热带疾病诊断市场将以 4.9% 的复合年增长率成长。这个市场的主要驱动力是被忽视的热带疾病数量的增加、对快速诊断测试的需求不断增加以及对被忽视的热带疾病的认识不断提高。全球被忽视的热带疾病诊断市场的未来对于医院和诊所、家庭医疗保健和临床检测市场来说是充满希望的。

被忽视的热带疾病诊断市场洞察

Lucintel 预测，由于已开发国家越来越多地采用就地检验来检测登革热病毒，因此在预测期内登革热仍将是最大的细分市场。

在这个市场中，由于全球实验室数量不断增加以及临床实验室先进设备的可用性不断增加，临床实验室可能仍然是最大的细分市场。

由于熟练的医疗保健专业人员的存在以及该地区居家医疗中越来越多地采用就地检验服务，北美在预测期内可能仍然是最大的细分市场。

常问问题

Q1.市场成长预测如何？

A1. 预计 2024 年至 2030 年，全球被忽视的热带疾病诊断市场将以 4.9% 的复合年增长率成长。

Q2.影响市场成长的主要驱动因素有哪些？

A2. 该市场的主要驱动力是被忽视的热带疾病数量的增加、对快速诊断测试的需求不断增长以及对被忽视的热带疾病的认识不断提高。

Q3.市场的主要细分市场有哪些？

A3.被忽视的热带疾病诊断市场在医院/诊所、家庭医疗保健和临床检测市场的前景广阔。

Q4.市场上主要企业有哪些？

A4.参与被忽视热带疾病诊断的主要企业如下。

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计，由于已开发国家越来越多地采用就地检验来检测登革热病毒，因此在预测期内登革热仍将是最大的部分。

Q6. 未来五年预计哪个地区将成为最大的市场？

A6. 由于熟练的医疗保健专业人员的存在以及居家医疗中越来越多地采用就地检验服务，北美在预测期内将继续成为最大的细分市场。

Q7. 可以客製化报告吗？

A7. 是的，Lucintel 提供 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球被忽视的热带疾病诊断市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球被忽视的热带疾病诊断市场趋势（2018-2023）和预测（2024-2030）
  • 全球被忽视的热带疾病诊断市场：依疾病类型
    • 登革热
    • 屈公病热
    • 狂犬病
    • 淋巴丝虫病
    • 布鲁里溃疡
    • 食物中毒肺吸虫病
    • 包虫病
    • 麻风
    • 其他的
  • 全球被忽视的热带疾病诊断市场：依方法分类
    • 传统方法
    • 分子法
  • 全球被忽视的热带疾病诊断市场：按服务类型
    • 集中服务
    • 就地检验
  • 全球被忽视的热带疾病诊断市场：依最终用途分类
    • 医院和诊所
    • 家庭保健
    • 临床实验室
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球被忽视的热带疾病诊断市场（按地区）
  • 北美洲被忽视的热带疾病诊断市场
  • 欧洲被忽视的热带疾病诊断市场
  • 亚太地区被忽视的热带疾病诊断市场
  • 其他地区被忽视的热带疾病诊断市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 依疾病类型
    • 依方法
    • 按服务类型
    • 按最终用途
    • 按地区
  • 全球被忽视的热带疾病诊断市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球被忽视的热带疾病诊断市场的能力
    • 全球被忽视的热带疾病诊断市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems
简介目录

Neglected Tropical Disease Diagnosis Trends and Forecast

The future of the global neglected tropical disease diagnosis market looks promising with opportunities in the hospital and clinic, home healthcare, and clinical laboratory markets. The global neglected tropical disease diagnosis market is expected to grow with a CAGR of 4.9% from 2024 to 2030. The major drivers for this market are escalating number of overlooked tropical diseases, rising demand for rapid diagnostic tests, and mounting recognition of NTDs.

A more than 150-page report is developed to help in your business decisions.

Neglected Tropical Disease Diagnosis by Segment

The study includes a forecast for the global neglected tropical disease diagnosis by disease type, method, service type, end use, and region.

Neglected Tropical Disease Diagnosis Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Dengue
  • Chikungunya
  • Rabies
  • Lymphatic Filariasis
  • Buruli Ulcer
  • Foodborne Trematodiases
  • Echinococcosis
  • Leprosy
  • Others

Neglected Tropical Disease Diagnosis Market by Method [Shipment Analysis by Value from 2018 to 2030]:

  • Conventional Method
  • Molecular Method

Neglected Tropical Disease Diagnosis Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:

  • Centralized Service
  • Point-of-Care Testing

Neglected Tropical Disease Diagnosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital and Clinic
  • Home Healthcare
  • Clinical Laboratories
  • Others

Neglected Tropical Disease Diagnosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Neglected Tropical Disease Diagnosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neglected tropical disease diagnosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neglected tropical disease diagnosis companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems

Neglected Tropical Disease Diagnosis Market Insights

Lucintel forecasts that dengue will remain the largest segment over the forecast period due to increasing adoption of point-of-care testing for dengue virus detection in developed nations.

Within this market, clinical laboratory will remain the largest segment due to increased number of laboratories across world and rising availability of advanced equipment in clinical laboratories.

North America will remain the largest segment over the forecast period due to existence of skilled healthcare professionals and growing adoption of point-of-care testing services at home healthcare in the region.

Features of the Global Neglected Tropical Disease Diagnosis Market

Market Size Estimates: Neglected tropical disease diagnosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neglected tropical disease diagnosis market size by various segments, such as by disease type, method, service type, end use, and region in terms of value ($B).

Regional Analysis: Neglected tropical disease diagnosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different disease types, methods, service types, end uses, and regions for the neglected tropical disease diagnosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neglected tropical disease diagnosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for neglected tropical disease diagnosis market?

Answer: The global neglected tropical disease diagnosis market is expected to grow with a CAGR of 4.9% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the neglected tropical disease diagnosis market?

Answer: The major drivers for this market are escalating number of overlooked tropical diseases, rising demand for rapid diagnostic tests and mounting recognition of ntds.

Q3. What are the major segments for neglected tropical disease diagnosis market?

Answer: The future of the neglected tropical disease diagnosis market looks promising with opportunities in the hospital and clinic, home healthcare, and clinical laboratory markets.

Q4. Who are the key neglected tropical disease diagnosis market companies?

Answer: Some of the key neglected tropical disease diagnosis companies are as follows.

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • InBios International
  • Omega Diagnostics
  • Oscar Medicare
  • EUROIMMUN
  • Novartis
  • Grifols
  • ZeptoMetrix
  • DiaSys Diagnostic Systems

Q5. Which neglected tropical disease diagnosis market segment will be the largest in future?

Answer: Lucintel forecasts that dengue will remain the largest segment over the forecast period due to increasing adoption of point-of-care testing for dengue virus detection in developed nations.

Q6. In neglected tropical disease diagnosis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to existence of skilled healthcare professionals and growing adoption of point-of-care testing services at home healthcare in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the neglected tropical disease diagnosis market by disease type (dengue, chikungunya, rabies, lymphatic filariasis, buruli ulcer, foodborne trematodiases, echinococcosis, leprosy, and others), method (conventional method and molecular method), service type (centralized service and point-of-care testing), end use (hospital and clinic, home healthcare, clinical laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neglected Tropical Disease Diagnosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Neglected Tropical Disease Diagnosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Neglected Tropical Disease Diagnosis Market by Disease Type
    • 3.3.1: Dengue
    • 3.3.2: Chikungunya
    • 3.3.3: Rabies
    • 3.3.4: Lymphatic Filariasis
    • 3.3.5: Buruli Ulcer
    • 3.3.6: Foodborne Trematodiases
    • 3.3.7: Echinococcosis
    • 3.3.8: Leprosy
    • 3.3.9: Others
  • 3.4: Global Neglected Tropical Disease Diagnosis Market by Method
    • 3.4.1: Conventional Method
    • 3.4.2: Molecular Method
  • 3.5: Global Neglected Tropical Disease Diagnosis Market by Service Type
    • 3.5.1: Centralized Service
    • 3.5.2: Point-of-Care Testing
  • 3.6: Global Neglected Tropical Disease Diagnosis Market by End Use
    • 3.6.1: Hospital and Clinic
    • 3.6.2: Home Healthcare
    • 3.6.3: Clinical Laboratories
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Neglected Tropical Disease Diagnosis Market by Region
  • 4.2: North American Neglected Tropical Disease Diagnosis Market
    • 4.2.2: North American Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others
  • 4.3: European Neglected Tropical Disease Diagnosis Market
    • 4.3.1: European Neglected Tropical Disease Diagnosis Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others
    • 4.3.2: European Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others
  • 4.4: APAC Neglected Tropical Disease Diagnosis Market
    • 4.4.1: APAC Neglected Tropical Disease Diagnosis Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others
    • 4.4.2: APAC Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others
  • 4.5: ROW Neglected Tropical Disease Diagnosis Market
    • 4.5.1: ROW Neglected Tropical Disease Diagnosis Market by Disease Type: Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Foodborne Trematodiases, Echinococcosis, Leprosy, and Others
    • 4.5.2: ROW Neglected Tropical Disease Diagnosis Market by End Use: Hospital and Clinic, Home Healthcare, Clinical Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Disease Type
    • 6.1.2: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Method
    • 6.1.3: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Service Type
    • 6.1.4: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by End Use
    • 6.1.5: Growth Opportunities for the Global Neglected Tropical Disease Diagnosis Market by Region
  • 6.2: Emerging Trends in the Global Neglected Tropical Disease Diagnosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Neglected Tropical Disease Diagnosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neglected Tropical Disease Diagnosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Thermo Fisher Scientific
  • 7.3: InBios International
  • 7.4: Omega Diagnostics
  • 7.5: Oscar Medicare
  • 7.6: EUROIMMUN
  • 7.7: Novartis
  • 7.8: Grifols
  • 7.9: ZeptoMetrix
  • 7.10: DiaSys Diagnostic Systems